
Najat C Daw

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5717920/publications.pdf Version: 2024-02-01



Νλιάτ C Πάλμ

#	Article	IF	CITATIONS
1	Correlation of nuclear pIGF-1R/IGF-1R and YAP/TAZ in a tissue microarray with outcomes in osteosarcoma patients. Oncotarget, 2022, 13, 521-533.	0.8	4
2	White paper: Oncoâ€fertility in pediatric patients with Wilms tumor. International Journal of Cancer, 2022, , .	2.3	5
3	The androgen receptor is a therapeutic target in desmoplastic small round cell sarcoma. Nature Communications, 2022, 13, .	5.8	14
4	Estimation of tumor cell total mRNA expression in 15 cancer types predicts disease progression. Nature Biotechnology, 2022, 40, 1624-1633.	9.4	31
5	Metabolic compensation activates pro-survival mTORC1 signaling upon 3-phosphoglycerate dehydrogenase inhibition in osteosarcoma. Cell Reports, 2021, 34, 108678.	2.9	33
6	Transcriptional activators YAP/TAZ and AXL orchestrate dedifferentiation, cell fate, and metastasis in human osteosarcoma. Cancer Gene Therapy, 2021, 28, 1325-1338.	2.2	13
7	Case Discussion and Literature Review: Cancer Immunotherapy, Severe Immune-Related Adverse Events, Multi-Inflammatory Syndrome, and Severe Acute Respiratory Syndrome Coronavirus 2. Frontiers in Oncology, 2021, 11, 625707.	1.3	7
8	A Phase I Trial of the MET/ALK/ROS1 Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid Malignancies. OncoTargets and Therapy, 2021, Volume 14, 3037-3049.	1.0	2
9	Impact of the First Generation of Children's Oncology Group Clinical Trials on Clinical Practice for Wilms Tumor. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 978-985.	2.3	26
10	Prognostic Value of Cell-Surface Vimentin-Positive CTCs in Pediatric Sarcomas. Frontiers in Oncology, 2021, 11, 760267.	1.3	5
11	Primary Ewing Sarcoma/Primitive Neuroectodermal Tumor of the Kidney: The MD Anderson Cancer Center Experience. Cancers, 2020, 12, 2927.	1.7	12
12	A prospective study of pediatric and adolescent renal cell carcinoma: A report from the Children's Oncology Group AREN0321 study. Cancer, 2020, 126, 5156-5164.	2.0	19
13	Activity of Vincristine and Irinotecan in Diffuse Anaplastic Wilms Tumor and Therapy Outcomes of Stage II to IV Disease: Results of the Children's Oncology Group AREN0321 Study. Journal of Clinical Oncology, 2020, 38, 1558-1568.	0.8	50
14	IGF-1R/mTOR Targeted Therapy for Ewing Sarcoma: A Meta-Analysis of Five IGF-1R-Related Trials Matched to Proteomic and Radiologic Predictive Biomarkers. Cancers, 2020, 12, 1768.	1.7	20
15	Immuno-genomic landscape of osteosarcoma. Nature Communications, 2020, 11, 1008.	5.8	143
16	Aerosolized Chemotherapy for Osteosarcoma. Advances in Experimental Medicine and Biology, 2020, 1257, 67-73.	0.8	6
17	Treatment of stage I anaplastic Wilms' tumour: a report from the Children's Oncology Group AREN0321 study. European Journal of Cancer, 2019, 118, 58-66.	1.3	32
18	Alpha Particle Radium 223 Dichloride in High-risk Osteosarcoma: A Phase I Dose Escalation Trial. Clinical Cancer Research, 2019, 25, 3802-3810.	3.2	42

NAJAT C DAW

#	Article	IF	CITATIONS
19	Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma. Clinical Genitourinary Cancer, 2019, 17, 1-6.	0.9	60
20	Prognostic Value of Metabolic and Volumetric Parameters of FDG PET in Pediatric Osteosarcoma: A Hypothesis-generating Study. Radiology, 2018, 287, 303-312.	3.6	25
21	Clinical Activity of Pazopanib in Patients with Advanced Desmoplastic Small Round Cell Tumor. Oncologist, 2018, 23, 360-366.	1.9	36
22	Analysis of HSP27 and the Autophagy Marker LC3B+ Puncta Following Preoperative Chemotherapy Identifies High-Risk Osteosarcoma Patients. Molecular Cancer Therapeutics, 2018, 17, 1315-1323.	1.9	13
23	¹⁸ F-FDG Uptake During Early Adjuvant Chemotherapy Predicts Histologic Response in Pediatric and Young Adult Patients with Osteosarcoma. Journal of Nuclear Medicine, 2018, 59, 25-30.	2.8	39
24	Health-Related Quality of Life and Survival Outcomes of Pediatric Patients With Nonmetastatic Osteosarcoma Treated in Countries With Different Resources. Journal of Global Oncology, 2018, 4, 1-11.	0.5	1
25	Tumor thrombus in the large veins draining primary pelvic osteosarcoma on cross sectional imaging. European Journal of Radiology, 2018, 105, 49-55.	1.2	13
26	Multimodality Treatment of Desmoplastic Small Round Cell Tumor: Chemotherapy and Complete Cytoreductive Surgery Improve Patient Survival. Clinical Cancer Research, 2018, 24, 4865-4873.	3.2	68
27	Multi-level otsu method to define metabolic tumor volume in positron emission tomography. American Journal of Nuclear Medicine and Molecular Imaging, 2018, 8, 373-386.	1.0	1
28	PET/CT of Osteosarcoma and Ewing Sarcoma. Seminars in Roentgenology, 2017, 52, 255-268.	0.2	14
29	A phase II trial evaluating the feasibility of adding bevacizumab to standard osteosarcoma therapy. International Journal of Cancer, 2017, 141, 1469-1477.	2.3	42
30	Prospective study of neuropathic pain after definitive surgery for extremity osteosarcoma in a pediatric population. Pediatric Blood and Cancer, 2017, 64, e26162.	0.8	19
31	Ewing sarcoma family of tumors in children younger than 10 years of age. Pediatric Blood and Cancer, 2017, 64, e26275.	0.8	14
32	¹⁸ F-FDG PET/CT as an Indicator of Survival in Ewing Sarcoma of Bone. Journal of Cancer, 2017, 8, 2892-2898.	1.2	27
33	Local Control Modality and Outcome for Ewing Sarcoma of the Femur: A Report From the Children's Oncology Group. Annals of Surgical Oncology, 2016, 23, 3541-3547.	0.7	8
34	A phase II study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcoma. Pediatric Blood and Cancer, 2016, 63, 1761-1770.	0.8	71
35	Comparison of ¹⁸ F-FDG-PET-CT and Bone Scintigraphy for Evaluation of Osseous Metastases in Newly Diagnosed and Recurrent Osteosarcoma. Pediatric Blood and Cancer, 2016, 63, 1381-1386.	0.8	81
36	IGF-1R and mTOR Blockade: Novel Resistance Mechanisms and Synergistic Drug Combinations for Ewing Sarcoma. Journal of the National Cancer Institute, 2016, 108, djw182.	3.0	49

Najat C Daw

#	Article	IF	CITATIONS
37	Bevacizumab dosing strategy in paediatric cancer patients based on population pharmacokinetic analysis with external validation. British Journal of Clinical Pharmacology, 2016, 81, 148-160.	1.1	38
38	Cardiovascular involvement by osteosarcoma: an analysis of 20 patients. Pediatric Radiology, 2016, 46, 21-33.	1.1	27
39	Prognostic Factors and Patterns of Relapse in Ewing Sarcoma Patients Treated With Chemotherapy and R0 Resection. International Journal of Radiation Oncology Biology Physics, 2015, 92, 349-357.	0.4	23
40	Influence of bony resection margins and surgicopathological factors on outcomes in limbâ€sparing surgery for extremity osteosarcoma. Pediatric Blood and Cancer, 2015, 62, 246-251.	0.8	32
41	Population Pharmacokinetics of Bevacizumab in Children with Osteosarcoma: Implications for Dosing. Clinical Cancer Research, 2014, 20, 2783-2792.	3.2	37
42	Photons or Protons for Non–Central Nervous System Solid Malignancies in Children: A Historical Perspective and Important Highlights. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, 33, e354-e359.	1.8	3
43	Analysis of prognostic factors in ewing sarcoma family of tumors. Cancer, 2007, 110, 375-384.	2.0	211